Skip Navigation


eCAM Advance Access originally published online on October 15, 2007
eCAM 2009 6(3):283-295; doi:10.1093/ecam/nem138
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
6/3/283    most recent
nem138v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Vojdani, A.
Right arrow Articles by Raxlen, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vojdani, A.
Right arrow Articles by Raxlen, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Novel Diagnosis of Lyme Disease: Potential for CAM Intervention

Aristo Vojdani1, Frank Hebroni2, Yaniv Raphael3, Jonathan Erde4 and Bernard Raxlen5

1Immunosciences Laboratory, Inc., Beverly Hills, CA 90211, 2Department of Psychobiology, University of California, 3Department of Biology, University of Southern California, 4Department of Biochemistry, University of California and 5Raxlen Clinic, New York, NY 10024, USA

Lyme disease (LD) is the most common tick-borne disease in the northern hemisphere, producing a wide range of disabling effects on multiple human targets, including the skin, the nervous system, the joints and the heart. Insufficient clinical diagnostic methods, the necessity for prompt antibiotic treatment along with the pervasive nature of infection impel the development and establishment of new clinical diagnostic tools with increased accuracy, sensitivity and specificity. The goal of this article is 4-fold: (i) to detail LD infection and pathology, (ii) to review prevalent diagnostic methods, emphasizing inherent problems, (iii) to introduce the usage of in vivo induced antigen technology (IVIAT) in clinical diagnostics and (iv) to underscore the relevance of a novel comprehensive LD diagnostic approach to practitioners of Complementary and Alternative Medicine (CAM). Utilization of this analytical method will increase the accuracy of the diagnostic process and abridge the time to treatment, with antibiotics, herbal medicines and nutritional supplements, resulting in improved quality of care and disease prognosis.

Keywords: Borrelia burgdorferi – in vivo-induced antigen technology – Lyme disease – multi-peptide ELISA

For reprints and all correspondence: Aristo Vojdani, Immunosciences Lab., Inc., 8693 Wilshire Blvd., Suite 200, Beverly Hills, CA 90211, USA. Tel: +1-310-657-1077; Fax: +1-310-657-1053; E-mail: drari{at}msn.com

Received May 16, 2007; accepted August 15, 2007


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.